Adiso Therapeutics
Biotechnology, 737 N 5th St, Concord, Massachusetts, 23219, United States, 11-50 Employees
Who is ADISO THERAPEUTICS
At Adiso, we create medicines to treat inflammatory diseases, improving the lives of patients and their families. Current treatment paradigms are far too often either inadequate to halt d...
Read More
-
Headquarters: 737 N 5th St, Concord, Massachusetts, 23219, United States
-
Date Founded: 2022
-
Employees: 11-50
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
-
CEO:
Scott Megaffin
Email
Phone
Industry: Biotechnology
SIC Code: 2836
|
NAICS Code: 541714 |
Show More
Does something look wrong? Fix it. | View contact records from ADISO THERAPEUTICS
Adiso Therapeutics Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Adiso Therapeutics
Answer: Adiso Therapeutics's headquarters are located at 737 N 5th St, Concord, Massachusetts, 23219, United States
Answer: Adiso Therapeutics's official website is https://adisotx.com
Answer: Adiso Therapeutics's revenue is $10 Million to $25 Million
Answer: Adiso Therapeutics's SIC: 2836
Answer: Adiso Therapeutics's NAICS: 541714
Answer: Adiso Therapeutics has 11-50 employees
Answer: Adiso Therapeutics is in Biotechnology
Answer: Adiso Therapeutics contact info: Phone number: Website: https://adisotx.com
Answer: At Adiso, we create medicines to treat inflammatory diseases, improving the lives of patients and their families. Current treatment paradigms are far too often either inadequate to halt disease progression or burden the patient with significant safety concerns. To tackle these challenges, we are advancing an innovative pipeline of small molecules and single strain live biotherapeutic products (SS-LBP) both with novel mechanisms of action. ADS024 (SS-LBP) is currently being evaluated in a Phase 1b study for the prevention of recurrent CDI and a Phase 2 study in mild-to-moderate ulcerative colitis (UC). ADS051 is currently enrolling a Ph1b study in moderate-to-severe ulcerative colitis (UC). Adiso is also developing a novel dual inflammasome inhibitor in discovery phase which is being initially explored in respiratory inflammation, with multiple future therapeutic areas to pursue.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
CEO at Adiso Therapeutics
Sign in to CIENCE GO Data to uncover contact details
Free credits every month